Pulmonary Hypertension:  Pathophysiology and Novel Therapies

Director : Professor Marc HUMBERT


Preclinical research
Clinical research
Hôpital Marie Lannelongue 
Département de recherche médicale
133, Avenue de la Résistance
92350 Le Plessis-Robinson, France
Hôpital Bicêtre
Service de Pneumologie et Réanimation Respiratoire
Centre National de Référence de l'Hypertension Pulmonaire
78 Rue du Général Leclerc
94270 Le Kremlin-Bicêtre, France


Pulmonary hypertension describes a group of devastating diseases, comprising idiopathic and associated forms, causing breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure. Pulmonary arterial hypertension is defined by an elevation of the mean pulmonary artery pressure above 25mmHg at rest and/or 30mmHg during exercise without elevation of the pulmonary capillary wedge pressure. Extensive pulmonary artery remodeling with loss of vessel patency is the underlying pathomechanism. The main scope of the Research Team "PULMONARY HYPERTENSION: PATHOPHYSIOLOGY AND NOVEL THERAPIES" relates to pulmonary hypertension pathophysiology and clinical management. Deciphering of the mechanisms of lung vascular remodeling and identification of novel molecular targets to alleviate and ultimately cure pulmonary hypertension is the main objective of this proposal. On the basis of a nationwide web-based Registry, a biobank, and highly competitive scientists, our group will study a number of molecular pathways causing pulmonary vascular remodeling in human and animal models of pulmonary hypertension, identify targets for therapy, foster drug development based on these targets and test novel treatments. Our main goal is to alleviate and cure pulmonary hypertension, a large burden to mankind, and to develop novel therapies.